[1]
Carriere V, Roussel L, Ortega N, et al. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proceedings of the National Academy
of Sciences of the United States of America 2007; 104(1): 282-7.
[2]
Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005; 23(5): 479-90.
[3]
Allakhverdi Z, Smith DE, Comeau MR, Delespesse G. Cutting edge: The ST2 ligand IL-33 potently activates and drives maturation of human mast cells. J Immunol 2007; 179(4): 2051-4.
[4]
Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005; 23(5): 479-90.
[5]
Smithgall MD, Comeau MR, Park Yoon B-R, Kaufman D, Armitage R, Smith DE. IL-33 amplifies both Th1-and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells. Int Immunol 2008; 20(8): 1019-30.
[6]
Palmer G, Talabot‐Ayer D, Lamacchia C, et al. Inhibition of interleukin‐33 signaling attenuates the severity of experimental arthritis. Arth Rheum 2009; 60(3): 738-49.
[7]
Xu D, Chan WL, Leung BP, et al. Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells. J Exp Med 1998; 187(5): 787-94.
[8]
Oshikawa K, Kuroiwa K, Tago K, et al. Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation. Am J Respir Crit Care Med 2001; 164(2): 277-81.
[9]
Prefontaine D, Lajoie-Kadoch S, Foley S, et al. Increased expression of IL-33 in severe asthma: evidence of expression by airway smooth muscle cells. J Immunol 2009; 183(8): 5094-103.
[10]
Zhang G, Lu J, Yin X, Sun Y, Li S. Association of IL-33, IL1RL1 gene polymorphisms with serum IL-33 levels and risk of asthma in adults and asthmatic bronchitis in children (Chinese). Biotechnol Biotechnol Equip 2018; 1: 1-6.
[11]
Kondo Y, Yoshimoto T, Yasuda K, et al. Administration of IL-33 induces airway hyperresponsiveness and goblet cell hyperplasia in the lungs in the absence of adaptive immune system. Int Immunol 2008; 20(6): 791-800.
[12]
Prefontaine D, Nadigel J, Chouiali F, et al. Increased IL-33 expression by epithelial cells in bronchial asthma. J Allergy Clin Immunol 2010; 125(3): 752-4.
[13]
Gudbjartsson DF, Bjornsdottir US, Halapi E, et al. Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction. Nat Genet 2009; 41(3): 342-7.
[14]
Zhang Y, Moffatt MF, Cookson WO. Genetic and genomic approaches to asthma: new insights for the origins. Curr Opin Pulm Med 2012; 18(1): 6-13.
[15]
Grotenboer NS, Ketelaar ME, Koppelman GH, Nawijn MC. Decoding asthma: translating genetic variation in IL33 and IL1RL1 into disease pathophysiology. J Allergy Clin Immunol 2013; 131(3): 856-65.
[16]
Shimizu M, Matsuda A, Yanagisawa K, et al. Functional SNPs in the distal promoter of the ST2 gene are associated with atopic dermatitis. Hum Mol Genet 2005; 14(19): 2919-27.
[17]
Lingel A, Weiss TM, Niebuhr M, et al. Structure of IL-33 and its interaction with the ST2 and IL-1RAcP receptors--insight into heterotrimeric IL-1 signaling complexes. Structure 2009; 17(10): 1398-410.
[18]
Liew FY, Pitman NI, McInnes IB. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol 2010; 10(2): 103-10.
[19]
Queiroz GdA, Costa RdS, Alcantara‐Neves N, et al. IL33 and IL1RL1 variants are associated with asthma and atopy in a Brazilian population. Int J Immunogenet 2017; 44(2): 51-61.
[20]
Grotenboer NS, Ketelaar ME, Koppelman GH, Nawijn MC. Decoding asthma: translating genetic variation in IL33 and
IL1RL1 into disease pathophysiology. J Allergy Clin Immunol
Pract 2013; 131(3): 856-65. e9..
[21]
Smith D. IL‐33: a tissue derived cytokine pathway involved in allergic inflammation and asthma. Clin Exp Allergy 2010; 40(2): 200-8.
[22]
Oksenberg JR, Baranzini SE. Multiple sclerosis genetics--is the glass half full, or half empty? Nat Rev Neurol 2010; 6(8): 429-37.
[23]
Xu D, Jiang H-R, Kewin P, et al. IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proceedings of the
National Academy of Sciences 2008; 105(31): 10913-8.
[24]
Latiano A, Palmieri O, Pastorelli L, et al. Associations between genetic polymorphisms in IL-33, IL1R1 and risk for inflammatory bowel disease. PLoS One 2013; 8(4): e62144.
[25]
Hudson CA, Christophi GP, Gruber RC, Wilmore JR, Lawrence DA, Massa PT. Induction of IL-33 expression and activity in central nervous system glia. J Leukoc Biol 2008; 84(3): 631-43.
[26]
Christophi GP, Gruber RC, Panos M, Christophi RL, Jubelt B, Massa PT. Interleukin-33 upregulation in peripheral leukocytes and CNS of multiple sclerosis patients. Clin Immunol 2012; 142(3): 308-19.
[27]
Jiang HR, Milovanovic M, Allan D, et al. IL-33 attenuates EAE by suppressing IL-17 and IFN-gamma production and inducing alternatively activated macrophages. Eur J Immunol 2012; 42(7): 1804-14.
[28]
Oboki K, Ohno T, Kajiwara N, Saito H, Nakae S. IL-33 and IL-33 receptors in host defense and diseases. Allergol Int 2010; 59(2): 143-60.
[29]
Christophi GP, Panos M, Hudson CA, et al. Interferon-β treatment in multiple sclerosis attenuates inflammatory gene expression through inducible activity of the phosphatase SHP-1. Clin Immunol 2009; 133(1): 27-44.
[30]
Christophi GP, Hudson CA, Panos M, Gruber RC, Massa PT. Modulation of macrophage infiltration and inflammatory activity by the phosphatase SHP-1 in virus-induced demyelinating disease. J Virol 2009; 83(2): 522-39.
[31]
Jiang HR, Milovanović M, Allan D, et al. IL‐33 attenuates EAE by suppressing IL‐17 and IFN‐γ production and inducing alternatively activated macrophages. Eur J Immunol 2012; 42(7): 1804-14.
[32]
Miller AM. Role of IL-33 in inflammation and disease. Journal
of inflammation (London, England) 2011; 8(1): 22.
[33]
Préfontaine D, Lajoie-Kadoch S, Foley S, et al. Increased expression of IL-33 in severe asthma: evidence of expression by airway smooth muscle cells. J Immunol 2009; 183(8): 5094-103.
[34]
Alsahebfosoul F, Rahimmanesh I, Shajarian M, et al. Interleukin-33 plasma levels in patients with relapsing-remitting multiple sclerosis. Biomol Concepts 2017; 8(1): 55-60.
[35]
Theoharides TC, Petra AI, Taracanova A, Panagiotidou S, Conti P. Targeting IL-33 in autoimmunity and inflammation. J Pharmacol Exp Ther 2015; 354(1): 24-31.
[36]
Miller AM. Role of IL-33 in inflammation and disease. J Inflamm 2011; 8: 22.
[37]
Sayed BA, Walker ME, Brown MA. Cutting edge: mast cells regulate disease severity in a relapsing-remitting model of multiple sclerosis. J Immunol 2011; 186(6): 3294-8.
[38]
Iikura M, Suto H, Kajiwara N, et al. IL-33 can promote survival, adhesion and cytokine production in human mast cells. Lab Invest 2007; 87(10): 971-8.
[39]
Saluja R, Khan M, Church MK, Maurer M. The role of IL-33 and mast cells in allergy and inflammation. Clin Transl Allergy 2015; 5: 33.
[40]
Sawcer S, Hellenthal G, Pirinen M, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011; 476(7359): 214-9.
[41]
Beecham AH, Patsopoulos NA, Xifara DK, et al. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet 2013; 45(11): 1353-60.
[42]
Tahmasebi Z, Akbarian M, Mirkazemi S, et al. Interleukin-1 gene cluster and IL-1 receptor polymorphisms in Iranian patients with systemic lupus erythematosus. Rheumatol Int 2013; 33(10): 2591-6.
[43]
Charrad R, Kaabachi W, Berraies A, Hamzaoui K, Hamzaoui A. IL-33 gene variants and protein expression in pediatric Tunisian asthmatic patients. Cytokine 2018; 104: 85-91.
[44]
Moffatt MF, Gut IG, Demenais F, et al. A large-scale, consortium-based genomewide association study of asthma. N Engl J Med 2010; 363(13): 1211-21.
[45]
Schröder PC, Casaca VI, Illi S, et al. IL‐33 polymorphisms are associated with increased risk of hay fever and reduced regulatory T cells in a birth cohort. Pediatr Allergy Immunol 2016; 27(7): 687-95.
[46]
Castano R, Bossé Y, Endam LM, Desrosiers M. Evidence of association of interleukin-1 receptor-like 1 gene polymorphisms with chronic rhinosinusitis. Am J Rhinol Allergy 2009; 23(4): 377-84.
[47]
Christophi GP, Gruber RC, Panos M, Christophi RL, Jubelt B, Massa PT. Interleukin-33 upregulation in peripheral leukocytes and CNS of multiple sclerosis patients. Clin Immunol 2012; 142(3): 308-19.
[48]
Zhang F, Tossberg JT, Spurlock CF, Yao SY, Aune TM, Sriram S. Expression of IL‐33 and its epigenetic regulation in multiple sclerosis. Ann Clin Transl Neurol 2014; 1(5): 307-18.
[49]
Lill CM. Recent Advances and Future Challenges in the Genetics of Multiple Sclerosis. Front Neurol 2014; 5: 130.
[50]
Pei C, Barbour M, Fairlie‐Clarke KJ, Allan D, Mu R, Jiang HR. Emerging role of interleukin‐33 in autoimmune diseases. Immunology 2014; 141(1): 9-17.
[51]
Jamali M, Rostami Rad M, Anani Sarab G, Mahdavi R. IL-33 polymorphism rs1929992 and its association with susceptibility to different pattern of multiple sclerosis. TUMS 2018; 76(7): 446-51.
[52]
Ho JE, Chen W-Y, Chen M-H, et al. Common genetic variation at the IL1RL1 locus regulates IL-33/ST2 signaling. J Clin Invest 2013; 123(10): 4208-18.
28
3
1
1